Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Laparoscopy | 30 | 2014 | 492 | 3.530 |
Why?
|
| Prostatectomy | 14 | 2021 | 99 | 2.990 |
Why?
|
| Robotics | 15 | 2019 | 87 | 2.680 |
Why?
|
| Nephrectomy | 16 | 2020 | 91 | 2.640 |
Why?
|
| Prostatic Neoplasms | 12 | 2022 | 418 | 1.980 |
Why?
|
| Urologic Surgical Procedures | 7 | 2020 | 44 | 1.780 |
Why?
|
| Artificial Intelligence | 4 | 2025 | 179 | 1.630 |
Why?
|
| Cystectomy | 6 | 2018 | 35 | 1.580 |
Why?
|
| Kidney Neoplasms | 11 | 2025 | 160 | 1.450 |
Why?
|
| Urology | 7 | 2024 | 45 | 1.430 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 2025 | 43 | 1.210 |
Why?
|
| Robotic Surgical Procedures | 5 | 2021 | 161 | 1.210 |
Why?
|
| Urinary Bladder Neoplasms | 7 | 2018 | 105 | 1.150 |
Why?
|
| Urinary Incontinence | 2 | 2019 | 44 | 1.010 |
Why?
|
| Ureteroscopy | 4 | 2025 | 17 | 0.950 |
Why?
|
| Urologic Neoplasms | 3 | 2024 | 18 | 0.940 |
Why?
|
| Men's Health | 1 | 2024 | 12 | 0.910 |
Why?
|
| Ambulatory Care Facilities | 1 | 2024 | 105 | 0.860 |
Why?
|
| Urologists | 1 | 2023 | 3 | 0.810 |
Why?
|
| Kidney Transplantation | 4 | 2011 | 319 | 0.810 |
Why?
|
| Ureteral Obstruction | 4 | 2011 | 25 | 0.760 |
Why?
|
| Carcinoma, Renal Cell | 6 | 2023 | 103 | 0.750 |
Why?
|
| Endoscopy | 5 | 2025 | 110 | 0.720 |
Why?
|
| Humans | 75 | 2025 | 63449 | 0.700 |
Why?
|
| Umbilicus | 6 | 2012 | 16 | 0.690 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 24 | 0.640 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 60 | 0.630 |
Why?
|
| Ureteral Calculi | 1 | 2019 | 8 | 0.630 |
Why?
|
| Male | 46 | 2025 | 29893 | 0.620 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 124 | 0.620 |
Why?
|
| Aneurysm, False | 1 | 2019 | 52 | 0.600 |
Why?
|
| Triage | 1 | 2020 | 126 | 0.590 |
Why?
|
| Nephrostomy, Percutaneous | 2 | 2008 | 7 | 0.590 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.560 |
Why?
|
| Conservative Treatment | 1 | 2018 | 17 | 0.560 |
Why?
|
| Intraoperative Complications | 3 | 2015 | 91 | 0.530 |
Why?
|
| Living Donors | 4 | 2011 | 77 | 0.530 |
Why?
|
| Prostate | 6 | 2022 | 90 | 0.520 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 209 | 0.520 |
Why?
|
| Kidney Pelvis | 4 | 2010 | 13 | 0.520 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.520 |
Why?
|
| MicroRNAs | 5 | 2023 | 687 | 0.510 |
Why?
|
| Patient Positioning | 2 | 2015 | 49 | 0.510 |
Why?
|
| Postoperative Hemorrhage | 2 | 2015 | 40 | 0.490 |
Why?
|
| Minimally Invasive Surgical Procedures | 4 | 2014 | 129 | 0.480 |
Why?
|
| Intestinal Perforation | 1 | 2015 | 17 | 0.480 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 149 | 0.480 |
Why?
|
| Rectal Diseases | 1 | 2015 | 28 | 0.470 |
Why?
|
| Lymph Node Excision | 2 | 2015 | 46 | 0.460 |
Why?
|
| Pandemics | 1 | 2020 | 672 | 0.460 |
Why?
|
| Drug Therapy | 1 | 2014 | 56 | 0.430 |
Why?
|
| Postoperative Complications | 8 | 2021 | 1308 | 0.420 |
Why?
|
| Neoplasm Staging | 7 | 2021 | 509 | 0.420 |
Why?
|
| Treatment Outcome | 16 | 2025 | 5680 | 0.410 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 322 | 0.400 |
Why?
|
| Ureteral Neoplasms | 2 | 2025 | 8 | 0.390 |
Why?
|
| Kidney | 4 | 2020 | 446 | 0.380 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2013 | 41 | 0.380 |
Why?
|
| Laparoscopes | 3 | 2009 | 25 | 0.380 |
Why?
|
| Urinary Tract | 1 | 2012 | 8 | 0.380 |
Why?
|
| Middle Aged | 28 | 2025 | 17615 | 0.360 |
Why?
|
| Surgical Mesh | 1 | 2011 | 59 | 0.340 |
Why?
|
| Hernia, Inguinal | 1 | 2011 | 42 | 0.340 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 663 | 0.340 |
Why?
|
| Ureter | 3 | 2016 | 37 | 0.330 |
Why?
|
| Aged | 23 | 2025 | 14449 | 0.320 |
Why?
|
| Pliability | 1 | 2009 | 6 | 0.310 |
Why?
|
| Miniaturization | 1 | 2009 | 10 | 0.310 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2010 | 36 | 0.310 |
Why?
|
| Kidney Diseases | 2 | 2018 | 176 | 0.300 |
Why?
|
| Common Bile Duct Diseases | 1 | 2008 | 10 | 0.290 |
Why?
|
| Female | 27 | 2025 | 32883 | 0.290 |
Why?
|
| Rectal Fistula | 1 | 2008 | 21 | 0.290 |
Why?
|
| Nephrolithiasis | 1 | 2008 | 8 | 0.290 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2008 | 47 | 0.280 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 165 | 0.280 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 88 | 0.270 |
Why?
|
| Drainage | 1 | 2008 | 154 | 0.270 |
Why?
|
| Urinary Catheterization | 1 | 2006 | 21 | 0.260 |
Why?
|
| Butyrates | 1 | 2005 | 16 | 0.230 |
Why?
|
| Urinary Diversion | 1 | 2005 | 12 | 0.230 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 27 | 0.230 |
Why?
|
| Databases, Factual | 3 | 2020 | 873 | 0.230 |
Why?
|
| Aged, 80 and over | 10 | 2025 | 5463 | 0.220 |
Why?
|
| Retrospective Studies | 11 | 2025 | 6659 | 0.220 |
Why?
|
| Cytoskeletal Proteins | 2 | 2005 | 200 | 0.220 |
Why?
|
| Teaching Materials | 1 | 2024 | 12 | 0.220 |
Why?
|
| Natural Language Processing | 1 | 2024 | 48 | 0.220 |
Why?
|
| Adult | 18 | 2025 | 16826 | 0.220 |
Why?
|
| Efficiency, Organizational | 1 | 2024 | 96 | 0.210 |
Why?
|
| Prospective Studies | 6 | 2025 | 3293 | 0.210 |
Why?
|
| Health Literacy | 1 | 2024 | 85 | 0.210 |
Why?
|
| Prostate-Specific Antigen | 2 | 2021 | 76 | 0.200 |
Why?
|
| Comprehension | 1 | 2024 | 138 | 0.200 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 373 | 0.200 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2022 | 8 | 0.190 |
Why?
|
| Lasers, Solid-State | 1 | 2022 | 18 | 0.190 |
Why?
|
| Risk Assessment | 5 | 2020 | 2079 | 0.190 |
Why?
|
| Pelvic Bones | 1 | 2021 | 17 | 0.180 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2021 | 8 | 0.170 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2020 | 6 | 0.170 |
Why?
|
| Nomograms | 2 | 2021 | 18 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 2 | 2018 | 87 | 0.170 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 475 | 0.170 |
Why?
|
| Urethra | 3 | 2021 | 75 | 0.170 |
Why?
|
| Urogenital Neoplasms | 1 | 2020 | 5 | 0.170 |
Why?
|
| Length of Stay | 3 | 2014 | 812 | 0.160 |
Why?
|
| Urethral Stricture | 1 | 2021 | 69 | 0.160 |
Why?
|
| Contraindications | 2 | 2011 | 52 | 0.160 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2019 | 16 | 0.160 |
Why?
|
| Kidney Function Tests | 2 | 2009 | 37 | 0.150 |
Why?
|
| Neoplasm Grading | 4 | 2021 | 92 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2025 | 345 | 0.140 |
Why?
|
| Nephroureterectomy | 1 | 2018 | 2 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2023 | 525 | 0.140 |
Why?
|
| Organ Sparing Treatments | 1 | 2018 | 16 | 0.140 |
Why?
|
| Preoperative Care | 3 | 2021 | 193 | 0.140 |
Why?
|
| Crowdsourcing | 1 | 2018 | 15 | 0.140 |
Why?
|
| Ablation Techniques | 1 | 2018 | 24 | 0.140 |
Why?
|
| Patient Care Management | 1 | 2018 | 30 | 0.140 |
Why?
|
| Kidney Calculi | 1 | 2018 | 34 | 0.140 |
Why?
|
| Quality of Life | 3 | 2011 | 1229 | 0.140 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 455 | 0.140 |
Why?
|
| Incidence | 2 | 2014 | 1377 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 770 | 0.140 |
Why?
|
| Enoxaparin | 1 | 2017 | 18 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2021 | 443 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 507 | 0.130 |
Why?
|
| Surveys and Questionnaires | 3 | 2025 | 2681 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2018 | 583 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 259 | 0.130 |
Why?
|
| Heparin | 1 | 2017 | 116 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 536 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 724 | 0.120 |
Why?
|
| Incisional Hernia | 1 | 2015 | 14 | 0.120 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2015 | 13 | 0.120 |
Why?
|
| Lymphocele | 1 | 2015 | 5 | 0.120 |
Why?
|
| Social Media | 1 | 2018 | 128 | 0.120 |
Why?
|
| Equipment Failure | 1 | 2015 | 67 | 0.120 |
Why?
|
| Peritoneum | 1 | 2015 | 30 | 0.120 |
Why?
|
| Blood Vessels | 1 | 2015 | 62 | 0.120 |
Why?
|
| Survival Rate | 3 | 2018 | 851 | 0.110 |
Why?
|
| Administration, Intravesical | 1 | 2014 | 13 | 0.110 |
Why?
|
| Inpatients | 1 | 2017 | 305 | 0.110 |
Why?
|
| Operative Time | 1 | 2014 | 92 | 0.110 |
Why?
|
| Surgical Flaps | 1 | 2015 | 117 | 0.110 |
Why?
|
| Learning | 1 | 2015 | 182 | 0.110 |
Why?
|
| Prognosis | 3 | 2021 | 1749 | 0.100 |
Why?
|
| Equipment Design | 3 | 2009 | 352 | 0.100 |
Why?
|
| Pelvis | 2 | 2015 | 59 | 0.100 |
Why?
|
| Time Factors | 3 | 2025 | 3768 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 772 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 2176 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 2459 | 0.090 |
Why?
|
| Biopsy | 3 | 2021 | 443 | 0.090 |
Why?
|
| Risk Factors | 2 | 2020 | 5354 | 0.090 |
Why?
|
| Replantation | 1 | 2011 | 12 | 0.090 |
Why?
|
| Sutures | 1 | 2012 | 41 | 0.090 |
Why?
|
| Anastomosis, Surgical | 2 | 2012 | 114 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 373 | 0.090 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2011 | 31 | 0.090 |
Why?
|
| Young Adult | 5 | 2017 | 4695 | 0.090 |
Why?
|
| Urologic Diseases | 1 | 2010 | 17 | 0.090 |
Why?
|
| Tissue Donors | 1 | 2011 | 153 | 0.080 |
Why?
|
| Genes, Suppressor | 1 | 2010 | 7 | 0.080 |
Why?
|
| Feasibility Studies | 5 | 2011 | 568 | 0.080 |
Why?
|
| Warm Ischemia | 1 | 2009 | 3 | 0.080 |
Why?
|
| Matched-Pair Analysis | 1 | 2009 | 10 | 0.080 |
Why?
|
| Convalescence | 1 | 2009 | 18 | 0.080 |
Why?
|
| Prostatic Hyperplasia | 1 | 2009 | 20 | 0.080 |
Why?
|
| Blood Loss, Surgical | 1 | 2009 | 65 | 0.080 |
Why?
|
| Ischemia | 1 | 2011 | 205 | 0.080 |
Why?
|
| Urachus | 1 | 2008 | 3 | 0.080 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 245 | 0.080 |
Why?
|
| Vascular Neoplasms | 1 | 2008 | 17 | 0.070 |
Why?
|
| Analgesics | 1 | 2009 | 102 | 0.070 |
Why?
|
| gamma Catenin | 2 | 2005 | 6 | 0.070 |
Why?
|
| Desmoplakins | 2 | 2005 | 10 | 0.070 |
Why?
|
| Dissection | 1 | 2008 | 48 | 0.070 |
Why?
|
| Graft Survival | 1 | 2009 | 289 | 0.070 |
Why?
|
| Urinary Bladder | 1 | 2008 | 45 | 0.070 |
Why?
|
| Adenoma | 1 | 2008 | 70 | 0.070 |
Why?
|
| Perioperative Care | 1 | 2009 | 85 | 0.070 |
Why?
|
| Postoperative Care | 1 | 2008 | 123 | 0.070 |
Why?
|
| Cadherins | 2 | 2005 | 80 | 0.070 |
Why?
|
| Intraoperative Care | 1 | 2008 | 38 | 0.070 |
Why?
|
| Pain Measurement | 1 | 2009 | 345 | 0.070 |
Why?
|
| Hemostatics | 1 | 2008 | 26 | 0.070 |
Why?
|
| Pain, Postoperative | 1 | 2009 | 162 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2023 | 988 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 422 | 0.070 |
Why?
|
| Patient Simulation | 1 | 2008 | 72 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 279 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 2576 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 194 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2009 | 379 | 0.070 |
Why?
|
| Lidocaine | 1 | 2006 | 33 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 58 | 0.060 |
Why?
|
| Anesthetics, Local | 1 | 2006 | 71 | 0.060 |
Why?
|
| Animals | 5 | 2023 | 20663 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 433 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 348 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2025 | 2570 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 542 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2005 | 137 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 92 | 0.060 |
Why?
|
| Mice, Nude | 1 | 2005 | 277 | 0.060 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 229 | 0.060 |
Why?
|
| Disease Progression | 2 | 2020 | 1173 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 490 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2005 | 374 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 325 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 883 | 0.050 |
Why?
|
| Algorithms | 1 | 2008 | 1003 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 1470 | 0.050 |
Why?
|
| Watchful Waiting | 1 | 2022 | 29 | 0.050 |
Why?
|
| Hiccup | 1 | 2002 | 3 | 0.050 |
Why?
|
| Language | 1 | 2023 | 150 | 0.050 |
Why?
|
| Laryngeal Masks | 1 | 2002 | 26 | 0.050 |
Why?
|
| Anesthesia, General | 1 | 2002 | 46 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1094 | 0.050 |
Why?
|
| Gastroesophageal Reflux | 1 | 2002 | 92 | 0.040 |
Why?
|
| Cell Movement | 1 | 2023 | 454 | 0.040 |
Why?
|
| United States | 1 | 2014 | 7843 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 76 | 0.040 |
Why?
|
| Mice | 2 | 2023 | 10845 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 641 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 1147 | 0.040 |
Why?
|
| Suture Techniques | 2 | 2012 | 100 | 0.040 |
Why?
|
| Terminology as Topic | 2 | 2010 | 141 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2020 | 297 | 0.040 |
Why?
|
| Transfection | 1 | 2021 | 694 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 89 | 0.040 |
Why?
|
| Cadaver | 2 | 2009 | 128 | 0.040 |
Why?
|
| Vagina | 2 | 2009 | 83 | 0.040 |
Why?
|
| Proteus mirabilis | 1 | 2018 | 2 | 0.040 |
Why?
|
| Proteus Infections | 1 | 2018 | 2 | 0.040 |
Why?
|
| Diverticulum | 1 | 2018 | 12 | 0.040 |
Why?
|
| Abdominal Abscess | 1 | 2018 | 13 | 0.040 |
Why?
|
| Confidentiality | 1 | 2018 | 55 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 490 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2021 | 512 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 65 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 921 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 265 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 1644 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 712 | 0.030 |
Why?
|
| Gallbladder | 1 | 2014 | 40 | 0.030 |
Why?
|
| Laparotomy | 1 | 2014 | 52 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 99 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 44 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 215 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2011 | 129 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 67 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 26 | 0.020 |
Why?
|
| Equipment and Supplies | 1 | 2009 | 19 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2009 | 59 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 457 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2009 | 79 | 0.020 |
Why?
|
| Liver | 1 | 2014 | 855 | 0.020 |
Why?
|
| Models, Animal | 1 | 2009 | 235 | 0.020 |
Why?
|
| Vas Deferens | 1 | 2008 | 5 | 0.020 |
Why?
|
| Cystoscopy | 1 | 2008 | 17 | 0.020 |
Why?
|
| Seminal Vesicles | 1 | 2008 | 8 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 288 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2009 | 135 | 0.020 |
Why?
|
| Cryosurgery | 1 | 2008 | 28 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2008 | 46 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2008 | 63 | 0.020 |
Why?
|
| Swine | 1 | 2008 | 375 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2009 | 268 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2008 | 153 | 0.020 |
Why?
|
| Registries | 1 | 2009 | 888 | 0.020 |
Why?
|
| Lethal Dose 50 | 1 | 2005 | 16 | 0.010 |
Why?
|
| beta Catenin | 1 | 2005 | 96 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2009 | 727 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 207 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 612 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2005 | 311 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 1207 | 0.010 |
Why?
|
| Child | 1 | 2009 | 4526 | 0.010 |
Why?
|
| Adolescent | 1 | 2009 | 6245 | 0.010 |
Why?
|